Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Freesmeyer

Showing results (201-210 of 203) with videos related to

Pageof 21
Sort By:
You have reached the last page of results.This site can display upto 203 results.
Hematological Oncology|February 19, 2020
Baseline and interim PET-based outcome prediction in peripheral T-cell lymphoma: A subgroup analysis of the PETAL trialChristine Schmitz, Jan Rekowski, Stefan P Müller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 12, 2018
Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III TrialUlrich Dührsen, Stefan Müller, Bernd Hertenstein, et al.
Annals of Hematology|January 6, 2019
Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the "Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas" (PETAL) trialAndreas Hüttmann, Jan Rekowski, Stefan P Müller, et al.
Pageof 21

Showing results (201-210 of 203) with videos related to

Sort By:
Pageof 21
You have reached the last page of results.This site can display upto 203 results.
Hematological Oncology|February 19, 2020
Baseline and interim PET-based outcome prediction in peripheral T-cell lymphoma: A subgroup analysis of the PETAL trialChristine Schmitz, Jan Rekowski, Stefan P Müller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 12, 2018
Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III TrialUlrich Dührsen, Stefan Müller, Bernd Hertenstein, et al.
Annals of Hematology|January 6, 2019
Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the "Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas" (PETAL) trialAndreas Hüttmann, Jan Rekowski, Stefan P Müller, et al.
Pageof 21